Ustekinumab biosimilar (Mabpharm)

乌司奴单抗生物类似药（迈博药业）

Report date: 2025/12/29 09:30:59

Base Information

Drug NameUstekinumab biosimilar (Mabpharm)
Drug Alias NameCMAB-022
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-23 inhibitorsInterleukin-12 inhibitors
TargetsInterleukin-23Interleukin-12
Therapy Area/IndicationsPlaque psoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMabpharm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMabpharm Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A